Double-blind study with Duovent and placebo in 20 asthmatic children

Area of Science:

• Pediatric Pulmonology
• Pharmacology

Background:

• Bronchial asthma is a chronic respiratory condition affecting children.
• Effective management of pediatric asthma symptoms like cough and dyspnea is crucial.
• Peak expiratory flow (PEF) is a key indicator of lung function in asthma patients.

Purpose of the Study:

• To evaluate the efficacy and safety of Duovent compared to placebo in children with bronchial asthma.
• To assess the impact of Duovent on asthma symptoms and lung function parameters.

Main Methods:

• A double-blind, placebo-controlled study involving 20 children (5-14 years) with bronchial asthma.
• A crossover design was used, with patients receiving Duovent and placebo in alternating 1-week periods.
• Asthma symptoms (cough, dyspnea) and peak expiratory flow (PEF) were monitored.

Main Results:

• Duovent significantly reduced cough and dyspnea compared to placebo.
• A significant increase in peak expiratory flow (PEF) was observed with Duovent treatment.
• The therapeutic effects of Duovent persisted for at least 8 hours and were well-tolerated without adverse events.

Conclusions:

• Duovent is an effective and safe treatment for bronchial asthma in children.
• The study demonstrates both clinical and functional improvements in pediatric asthma patients using Duovent.
• Duovent met daily therapeutic needs, highlighting its practical utility in managing childhood asthma.